UNAIDS Urges Greater Access for Gilead’s Lenacapavir

By Rene Pretorius

October 16, 2024

The press statement from UNAIDS, dated October 2, 2024, highlights Gilead’s announcement regarding the breakthrough HIV medicine lenacapavir, offering several key insights and points of contention. UNAIDS welcomes Gilead’s decision to license the HIV medicine lenacapavir for generic production. This move is seen as crucial in stemming the tide of new HIV infections, particularly among young women and marginalized communities.

Access and Affordability

UNAIDS emphasizes the necessity of ensuring that lenacapavir access affordability. They applaud Gilead for licensing the medicine without waiting for registration, which could expedite its availability. However, UNAIDS expresses concern that the current licenses exclude many middle-income countries, where a significant portion of new HIV infections occur. They urge Gilead to secure further licenses to enhance access in all low- and middle-income nations.

Pricing Transparency

UNAIDS calls for Gilead to disclose the specific price of lenacapavir while providing full transparency on their costs. Researchers have suggested that lenacapavir could potentially be produced and sold for as little as $100 per patient per year, or even $40. This transparency is vital for ensuring that lenacapavir is both affordable and accessible.

Manufacturing and Sustainability

UNAIDS stresses the importance of manufacturing lenacapavir in African countries. They focus on countries with high HIV rates, to ensure the sustainability of supply. They suggest that involving manufacturers in countries like South Africa, which has a strong production capacity, would be particularly beneficial.

Treatment Use and Licensing

UNAIDS appreciates that Gilead’s license includes treatment use. However, they urge the company to remove the current limitation to “heavily treatment-experienced patients.” Doing so would allow for more flexible use of lenacapavir in treatment regimens and support scientists and manufacturers around the globe.

Global Commitment

The statement reaffirms UNAIDS’ commitment to ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals. They emphasize the need for leaving no one behind to unlock the full potential of lenacapavir and protect a generation from HIV.

In summary, while UNAIDS is optimistic about the potential of lenacapavir to dramatically improve HIV prevention. They highlight critical issues that must be addressed on lenacapavir access affordability. By focusing on affordability, manufacturing, and treatment flexibility, they believe lenacapavir can indeed make a significant impact in the fight against HIV.

Reference url

Recent Posts

Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurement Challenges

By João L. Carapinha

October 30, 2025

African Pharmaceutical Growth remains stifled by significant barriers, as highlighted in a recent plenary address at the Conference on Public Health in Africa (CPHIA) 2025 (reported by Health Policy Watch). Dr. Stavros Nicolaou, group senior executive for strategic trade at Aspen Pharmacare and c...
Aligning Medical Schemes with National Health Insurance South Africa
The National Health Insurance initiative in South Africa is advancing toward universal health coverage, and the recent CMS Annual Report 2024/25 highlighted the regulator's pivotal role in supporting this framework by integ...
Obesity Health Economics: Forecasting Trends and Costs in the US

By HEOR Staff Writer

October 29, 2025

Obesity health economics reveals a pressing public health crisis in the US, where rising prevalence drives massive costs and strains healthcare systems. If you're wondering how obesity impacts the economy, consider this: projections show annual expenses could surpass $1 trillion by 2040, fueled b...